NCT06807619View on ClinicalTrials.gov

A Study of Sotorasib in People With Brain Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 29, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2028

Conditions
Brain Tumor
Interventions
DRUG

Sotorasib

Enrolled patients will be administered DCOI at the FDA-recommended dose or continued on the DCOI at the discretion of the treating Oncologist per standard of care

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering West Harrison (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Commack (Limited Protocol Activities), Commack

RECRUITING

Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

Sponsors

Collaborators (1)

Amgen
All Listed Sponsors
collaborator

Amgen

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER